Ep. 352 - A Multipolar Biopharma World; Rare Disease Spotlight
Can a strong U.S. biopharma industry be reconciled with the successful emergence of China? And can China be a catalyst of positive change across the global industry, even if this implies some level of rebalancing away from the U.S.? On the latest BioCentury This Week podcast, BioCentury’s analysts discuss a Guest Commentary by McKinsey Senior Partner Emeritus Franck Le Deu, who argues that a multipolar biopharma world in which the U.S. continues to thrive even as China becomes meaningfully stronger can emerge.
The analysts also discuss BioCentury’s latest Rare Disease Spotlight, which focuses on a wave of therapies aiming to activate retinal function in Stargardt disease patients.
Turning to FDA, BioCentury Washington Editor Steve Usdin discusses recent public statements by FDA Commissioner Marty Makary, questions about Vinay Prasad’s future, and the plausible mechanism pathway.
View full story: https://www.biocentury.com/article/658606
#GlobalBiopharma #ChinaBiotech #RareDisease #StargardtDisease #FDAPolicy
00:00 - Introduction
02:47 - Multipolar Biopharma World
13:39 - Rare Disease Spotlight
25:15 - Makary Remarks
31:14 - Plausible Mechanism Framework
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
More description
Can a strong U.S. biopharma industry be reconciled with the successful emergence of China? And can China be a catalyst of positive change across the global industry, even if this implies some level of rebalancing away from the U.S.? On the latest BioCentury This Week podcast, BioCentury’s analysts discuss a Guest Commentary by McKinsey Senior Partner Emeritus Franck Le Deu, who argues that a multipolar biopharma world in which the U.S. continues to thrive even as China becomes meaningfully stronger can emerge.
The analysts also discuss BioCentury’s latest Rare Disease Spotlight, which focuses on a wave of therapies aiming to activate retinal function in Stargardt disease patients.
Turning to FDA, BioCentury Washington Editor Steve Usdin discusses recent public statements by FDA Commissioner Marty Makary, questions about Vinay Prasad’s future, and the plausible mechanism pathway.
View full story: https://www.biocentury.com/article/658606
#GlobalBiopharma #ChinaBiotech #RareDisease #StargardtDisease #FDAPolicy
00:00 - Introduction
02:47 - Multipolar Biopharma World
13:39 - Rare Disease Spotlight
25:15 - Makary Remarks
31:14 - Plausible Mechanism Framework
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
Listen elsewhere
Available Results
Generated results are saved to your library for reuse and search.